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The family of mammalian sialidases is composed of four distinct versatile enzymes that remove negatively charged
terminal sialic acid residues from gangliosides and glycoproteins in different subcellular areas and organelles,
including lysosomes, cytosol, plasma membrane and mitochondria. In this review we summarize the growing body
of data describing the important role of sialidases in skeletal muscle, a complex apparatus involved in numerous
key functions and whose functional integrity can be affected by various conditions, such as aging, chronic diseases,
cancer and neuromuscular disorders. In addition to supporting the proper catabolism of glycoconjugates, sialidases
can affect different signaling pathways by desialylation of many receptors and modulation of ganglioside content
in cell membranes, thus actively participating in myoblast proliferation, differentiation and hypertrophy, insulin
responsiveness and skeletal muscle architecture.
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The family of sialidases
Sialidases or neuraminidases (EC 3.2.1.18, systematic
name: acetylneuraminyl hydrolase) are glycohydrolases
widely distributed in nature, from viruses and microor-
ganisms such as bacteria, protozoa and fungi, to verte-
brates [1,2]. They catalyze the removal of the acidic
sugar sialic acid from a great variety of gangliosides and
glycoproteins, generally termed glycoconjugates, which
are mainly exposed on the cell surface or are secreted in
the extracellular matrix (ECM) [3]. The particular chem-
ical structure, the terminal position on oligosaccharide
antennas and the negative charge of sialic acid residues
confer special structural properties to glycoconjugates,
accounting for their biological relevance as key regulators
of molecular and cellular interactions [4]. Depending on
their ability to act on α-(2→3)-, α-(2→6)-, α-(2→8)-
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reproduction in any medium, provided the orα-(2→8)-sialosyl linkages in oligo- and poly-sialic acids,
sialidases are subdivided into exo- or endo-sialidases, re-
spectively [2,4]. Since the first cloning of a mammalian si-
alidase in 1993 boosted the research on these enzymes
[5], four distinct genes have been identified, encoding
the lysosomal NEU1, the cytosolic NEU2, the plasma
membrane-associated NEU3 and the mithocondrial/ER-
associated NEU4 types, as summarized in various general
reviews [2,6-8]. All of them behave as exo-sialidases and
have a significant degree of homology, sharing with mi-
crobial sialidases typical amino acid motifs, such as the Y
(F)RI(V)P motif in N-terminus and the so called Asp
boxes (SxDxGxxΦ, where Φ stands for an aromatic resi-
due) along the primary structure [2]. Over the past two
decades, the involvement of NEU1, NEU2 and NEU3
in the physiopathology of skeletal muscle has clearly
emerged from different studies, emphasizing that these
enzymes may affect the life of muscle cells by modifying
the cell content of sialylated lipids and proteins.The substrates of sialidases: gangliosides and
glycoproteins
To understand the role of sialidases in skeletal muscle, we
need to focus on their preferred substrates, which are
gangliosides and glycoproteins. Gangliosides are acidicl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[9-11], but also present in skeletal muscle [12-16]. They
are anchored on the outer leaflets of cell surfaces, with
the sphingosine and fatty acid chains of the ceramide
moiety embedded in the plasma membrane and the sugar
oligosaccharide chain with terminal sialic acid(s) protrud-
ing toward the extracellular surface [17]. Gangliosides are
involved in a plethora of physiological processes, such as
cell-cell recognition and adhesion [18] and regulation of
signal transduction in caveolae [19], lipid rafts [20] and
glycosphingolipid-enriched microdomains [21]. They are
also involved in the pathology of many diseases, such as
the Guillain-Barre syndrome caused by an auto-immune
response to surface gangliosides [22], influenza [23],
some lysosomal storage diseases including Tay-Sachs
disease (GM1 gangliosidosis), Sandhoff disease (GM2
gangliosidosis), sialidosis and galactosialidosis [24,25], an
infantile-onset symptomatic epilepsy syndrome caused
by ganglioside GM3 deficiency [26], type 2 diabetes [27]
and Alzheimer’s disease [28,29]. Interestingly, altered
GM3 levels have been recently found in the Hereditary
Inclusion Body Myopathy (HIBM, also known as Distal
Myopathy with Rimmed Vacuoles), a unique autosomal
recessive muscle disorder characterized by adult-onset of
muscle weakness in upper and lower limbs [30]. At the
molecular level, gangliosides may participate in the com-
position and organization of membranes [31] and serve as
modulators for several receptor proteins, usually limiting
their activities. Ganglioside GM3, one of the essential
components of plasma membrane rafts [32], is a nega-
tive regulator of insulin receptor (IR), as mice lacking
GM3 display enhanced insulin sensitivity [33]. In addition,
the coordinate enzymatic activity of sialidases and other
glycohydrolases toward gangliosides may generate bio-
active sphingolipids, such as ceramide, sphingosine and
sphingosine-1-phosphate [34,35], which have a variety of
important effects on the activation of muscle resident
stem cells, regulation of contractile properties, insulin re-
sponsiveness and muscle fiber nourishment [36].
Beyond the gangliosides, sialidases recognize and desia-
lylate glycoproteins involved in various functions, thus in-
fluencing many processes in different cell types [37].
Protein glycosylation may be of great importance during
myogenesis, as confirmed by the fact that its inhibition
impairs the fusion of myoblasts [38], but it is particularly
important to preserve the integrity of musculoskeletal tis-
sues in the post-natal age. In this regard, it is well accepted
that the aberrant glycosylation on the mucin domain of
α-dystroglycan, a member of the dystrophin-associated
glycoprotein (DAG) complex [39,40], is associated with
many forms of muscular dystrophy [40-43], commonly re-
ferred to as Dystroglycanopathies [44-46]. Recently, it has
been shown that sialidase NEU1 deficiency causes mus-
cle degeneration due to lack of processing toward yetunknown protein substrates [47], thus underlining the im-
portance of sialidases in preserving the integrity of skeletal
muscle by regulation of protein glycosylation.
Finally, free unbounded sialic acids are considered as
regulators that modulate the function of several voltage-
gated potassium and sodium channels responsible for the
generation of action potentials in myofibers, cardiomyo-
cytes and neurons [48,49]. On the basis of these prelimin-
ary observations, the ability of sialidases to modulate the
cell contents of sialylated molecules have important con-
sequences on muscle homeostasis, as described more in
detail below.
Functional role of sialidases in skeletal muscle
The following sections briefly summarize the main bio-
chemical features and biological functions of NEU1,
NEU2 and NEU3 and then discuss in detail their role in
skeletal muscle (see also Table 1 and Figure 1), with the
exception of NEU4 that, at present, seems to be less
involved in muscle development and/or physiology.
Lysosomal sialidase NEU1
NEU1 is a pivotal enzyme required to initiate the degrad-
ation of sialo-glycoconjugates in lysosomes [50], with pre-
ference for oligosaccharide and glycopeptide substrates
[51], even if the protein can hydrolyze gangliosides in the
presence of detergents or the sphingolipid activator Sapo-
sin B [52,53]. Newly synthesized NEU1 is transported
to lysosomes, where is complexed with β-galactosidase
(β-GAL) and the serine carboxypeptidase protective pro-
tein/cathepsin A (PPCA), the latter being specifically
required for its catalytic activity [54]. Two genetically dis-
tinct lysosomal storage diseases are associated with NEU1
deficiency: sialidosis (OMIM 256550), which results from
structural mutations at the NEU1 locus on chromosome
6p21 [55], and galactosialidosis (OMIM 256540), which is
caused by a primary defect of PPCA, leading to secondary
and combined deficiencies of NEU1 and β-GAL [56,57].
Depending on the levels of residual enzyme activity,
NEU1 deficiency promotes a progressive lysosomal accu-
mulation of sialylated glycopeptides, gangliosides and oli-
gosaccharides in several cell types, leading to a broad
spectrum of clinical manifestations such as abnormal som-
atic features, severe neurologic involvement and muscular
dysfunction due to muscle hypotonia, atrophy, and osteos-
keletal deformities [58]. These clinical symptoms have
suggested an important role for NEU1 in muscle homeo-
stasis, as deduced from the analysis of an inbred SM/J
mouse strain with defects in NEU1 expression [59-61] and
from the muscular phenotype of NEU1−/− mice [47].
Unlike dystrophic muscles, commonly characterized by
sarcolemmal damage, intense inflammatory response, cel-
lular necrosis and repeated cycles of muscle regeneration,
the muscle pathology of NEU1−/− mice was derived from
Table 1 Sialidases in skeletal muscle
NEU1 NEU2 NEU3 NEU4
Human chromosomal
localization
6p21.31 2q37.1 11q13.5 2q37.3
Human disorders due to
inherited deficiency
Sialidosis and Galactosialidosis [55] none none none
Sialidase animal models NEU1 −/− mice exhibit muscle
degeneration [47]
none Transgenic NEU3 mice
develop insulin resistance [126]
none
Expression in myoblasts In vivo and in vitro [47,83,84] In vitro [5,89,92,93,97-99,
103,104,107]
In vivo and in vitro [126,137] not detected
Role proposed in
muscle cells
NEU1 regulates the ECM deposition
in skeletal muscle by limiting the
lysosomal exocytosis in the
fibroblasts sorrounding
the myofibers [47]
NEU2 silencing prevents
myoblast differentiation of
rat L6 myoblasts [99]
NEU3 behaves as a negative
regulator of glucose uptake [126]
NEU1 can desialylate both IR or
IGF1R and influence insulin
responsiveness [82]
NEU2 over-expression
enhances C2C12
differentiation [98]
NEU3 is involved in C2C12
myoblast fusion by controlling
the levels of GM3 [137]
NEU1 expression increases
during the early stages of
mouse C2C12 myoblast
differentiation [83]
NEU2 expression increases
through the PI3K/AKT pathway
during differentiation and
hypertrophy of C2C12
myotubes [103,104]
NEU3 over-expression delays
differentiation but finally
promotes the formation of
hypertrophic myotubes [138]
NEU1 over-expression
impairs C2C12
differentiation [84]
NEU2 is degraded through
an autophagic-dependent
pathway during atrophy of
C2C12 myotubes [104,107]
Muscle-derived tumors:
rhabdomyosarcomas
- NEU2 expression is undetectable
in the human embryonal RD
cells [109]
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rounding the basal lamina, leading to increased secretion
of proteolytic lysosomal cathepsins and metalloproteinases
that facilitate fibroblast proliferation and infiltration within
the juxtaposed myofibers [47]. Lysosomal exocytosis, a
calcium-dependent mechanism that allows the fusion of
specialized lysosomes in the plasma membrane and the re-
lease of their luminal content extracellularly [62-65], is
required during various physiological and pathological
processes, such as the repair of the plasma membrane, the
elimination of pathogenic bacteria or the release of HIV
from infected cells [66-69]. In this context, NEU1 was
previously found to negatively regulate the lysosomal exo-
cytosis in hematopoietic cells by processing the lysosomal-
associated membrane protein-1 (LAMP-1) protein [70]. In
skeletal muscle NEU1 plays a critical role in the control of
ECM deposition by limiting the lysosomal exocytosis in
fibroblasts surrounding the myofibers, although the mo-
lecular targets underlying this mechanism remain to be
elucidated. It is worth remembering that dystrophic mus-
cles are usually characterized by the occurrence of fibrotic
areas worsening the clinical outcome of patients. In this
regard, it may be important from a therapeutic point of
view to assess whether NEU1 may possibly influence by
receptor desialylation certain signaling pathways playing
a key role in muscle fibrosis, such as those dependenton the transforming growth factor beta (TGF-β) ligands
[71-75]. Beyond the lysosomes, NEU1 can indeed be tar-
geted to the cell surface in a multiprotein complex [76],
playing an active role in the desialylation of several ca-
nonical and non-canonical cell receptors [77,78]. For
instance, NEU1-mediated desialylation of integrin β4
leads to metastasis suppression in colon cancer [79,80],
whereas in arterial smooth muscle cells the NEU1-
dependent desialylation of both platelet-derived growth
factor receptor (PDGFR) and insulin-like growth factor-1
receptor (IGF1R) lowered their intracellular signals,
thereby diminishing cell proliferation [81]. In agreement
with this evidence, the NEU1-mediated desialylation of
both insulin receptor (IR) or IGF1R in L6 skeletal myo-
blasts leads to an increased or decreased cell proliferation
in response to low or high concentrations of insulin, re-
spectively, suggesting that NEU1 activity may influence
glucose uptake in myoblasts [82].
As well as having a central role in the control of
muscle architecture and responsiveness, NEU1 has been
implicated in the regulation of myogenesis, as deduced
from different in vitro studies. In this respect, it was
shown that the NEU1 promoter region contains a
CCAAT box and four E-boxes which serve to drive its
expression through a MyoD-dependent mechanism [83].
In particular, NEU1 expression is closely and temporally
Figure 1 (See legend on next page.)
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Figure 1 Cartoon depicting the role of sialidases during the multistep process of myogenesis. STEP 1: During myoblast proliferation, NEU1
is complexed with PPCA and β-GAL and its activity is mainly detectable within lysosomes, whereas plasma membrane-associated NEU3 is present
at low levels. On the other hand, the cytosolic NEU2 is absent. STEP 2: Myoblast fusion is characterized by an early and transient increase of NEU1
expression as well as by a long-lasting increment of both NEU2 and NEU3 expression, the latter being involved in cell-cell recognition by working
on gangliosides resident on the same cell (cis-activity) or on adjacent cells (trans-activity), as shown in the enlarged box. STEP 3: In differentiated
myotubes, NEU1 participates in the degradation of sialo-glycoconjugates in lysosomes but it is also targeted to the cell surface, where it may
desialylate IR and IGF1R, thus affecting their responsiveness to insulin. Since NEU1 limits the lysosomal exocytosis in the fibroblasts surrounding
the myofibers, NEU1 −/− mice exhibit muscle degeneration due to infiltration of connective tissues. In the cytosol of myotubes, NEU2 expression
is modulated mainly through the AKT pathway during hypertrophy and atrophy. In this compartment, cytosolic N-glycans may represent suitable
substrates of this enzyme. At the plasma membrane, NEU3 positively affects EGFR signaling by converting GM3 to lactosyl-ceramide, while it
blocks the IR activity by conversion of GD1a to GM1. Cell surface sialylated molecules, such as NCAM, may be a target of NEU3 activity. Note that
depiction of sugar chains corresponds to the simplified style used in [144].
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differentiation, while it is down-regulated in the late
stages through repression of the promoter activity by a
MEK1-dependent mechanism, suggesting that NEU1
levels must be finely tuned [84]. In support of this gene
regulation, constitutive NEU1 over-expression impaired
the differentiating process of C2C12 myoblasts [84], sug-
gesting that its constitutive over-activation may irrevers-
ibly affect the sialylation state and activity of some
surface molecules involved in myogenesis, such as
CD45, CD164 and the neural cell adhesion molecule
(NCAM) [85-88].
Overall, we may conclude that NEU1 plays a pleio-
tropic role in skeletal muscle, encompassing the control
of cell proliferation, differentiation and, above all, skel-
etal muscle architecture.
Cytosolic sialidase NEU2
In 1993 Miyagi et al. reported the first molecular cloning
of a mammalian sialidase encoding the sialidase NEU2
[5], a cytosolic enzyme expressed predominantly in skel-
etal muscle [89] and, to a lesser extent, in liver [90] and
thymus [91]. Two subsequent works confirmed that the
human NEU2 enzyme, sharing a high degree of hom-
ology with the rodent forms, is expressed in skeletal
muscle and shows a subcellular localization and bio-
chemical properties typical of the soluble sialidases
[92,93]. Protein crystallography studies revealed that the
human NEU2 consists of a six bladed β-propeller [94], a
structural organization that is typically conserved be-
tween viral and microbial sialidases [95]. Furthermore, a
detailed kinetic characterization has indicated that
NEU2 exhibits a broad substrate specificity toward gang-
liosides and several different glycoproteins [96]. On the
basis of sequence homologies, it is plausible to assume
that the other mammalian sialidases share with NEU2 a
conserved structural organization and a similar broad
substrate specificity. Because of its almost exclusive ex-
pression in musculoskeletal tissues, two initial studies
carried out in 1995 [97] and later in 2003 [98] point-
ed out the NEU2 involvement during differentiation ofskeletal myoblasts in vitro. In this regard, an increased
NEU2 gene transcription in rat L6 myoblasts appeared to
be dependent on the presence in the promoter region of
two pairs of E-box sequences, which are known binding
sites for muscle-specific transcription factors involved in
differentiation [97]. Subsequently, a similar transcriptional
NEU2 up-regulation was observed during differentiation
of mouse C2C12 myoblasts [98]. Indeed, a long-lasting in-
crease of NEU2 enzymatic activity can be detected in the
cytosolic fractions of myoblasts that are committed to dif-
ferentiate [98,99]. These initial studies also discovered that
altering NEU2 expression may influence the process of
differentiation, as NEU2 suppression impaired the fusion
process of L6 myoblasts [99], while over-expression of a
rat form inhibited the proliferation and improved the dif-
ferentiation in mouse C2C12 myoblasts [98]. To gain fur-
ther insights, NEU2 has been studied during hypertrophy
and atrophy. In this regard, the hypertrophy of C2C12
myotubes obtained via administration of IGF1 [100], vaso-
pressin [101] or histone deacetylase inhibitor Trichostatin
A [102] resulted in a significant increase in NEU2 tran-
scriptional and enzymatic levels [103,104]. Moreover, such
an increase is obtained through the activation of the
PI3K/AKT signaling pathway, the master controller of the
balance between protein synthesis and degradation in
skeletal muscle [105,106]. In this regard, the increase of
NEU2 activity assayed in hypertrophic C2C12 myotubes
as a result of the constitutive AKT signaling was particu-
larly impressive [103], suggesting that NEU2 may cooper-
ate as one of its downstream effectors in building skeletal
muscle. In agreement with this evidence, the atrophy of
myotubes induced by nutrient deprivation or treatment
with the glucocorticoid dexamethasone was relative to the
impaired activity of the PI3K/AKT pathway and was char-
acterized by a macroautophagic-dependent degradation of
NEU2 [104,107]. In this context, in vitro assays showed
that NEU2 is sensitive to the proteolytic action of the lyso-
somal cathepsins B and L [107], two isoforms with preva-
lent expression in skeletal muscle [108]. Finally, it is
interesting to note that NEU2 was also investigated in
human RD cells [109], which are cancerous cells deriving
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tumors composed of cell elements committed toward a
myoblast lineage [110-113]. NEU2 was undetectable in
RD cells and their partial myogenic differentiation
obtained using drug treatments was not sufficient to re-
store its expression [109]; this suggests that the loss of
NEU2, contributing to the impaired myoblast differenti-
ation, may favor the oncogenic process. Overall, this grow-
ing body of evidence underlines an important role of
NEU2, although not fully understood, in the fusion of
myoblasts and the growth of myofibers. In support of this
notion, it is intriguing that the impaired muscle regener-
ation observed in the SJL mouse, a model for human dys-
ferlinopathy, is characterized by NEU2 down-regulation
[114]. With regard to its potential substrates, it is believed
that they should preferentially be glycoproteins instead of
gangliosides, given the cytosolic localization of the en-
zyme. In this respect, it is of interest that NEU2 may par-
ticipate in the degradation of complex-type N-glycans in
the cytosol of MKN7 and MKN45 stomach cancer cells
[115]. N-linked glycosylation is the most common type of
post-translational modification playing a central role in
the onset of some muscular dystrophies [43,44,116], as
confirmed by the fact that mutations in DPAGT1, an
essential enzyme catalyzing the first committed step of
N-linked protein glycosylation, are responsible for a limb-
girdle congenital myasthenic syndrome with tubular aggre-
gates [117]. From this perspective, it is plausible that
NEU2 may facilitate the process of myogenesis by ensuring
the correct turn-over of glycosylated proteins through the
processing of free oligosaccharides or misfolded glycopro-
teins that are released into the cytosol.
Altogether, these observations indicate that further in-
vestigation is required to understand the role of NEU2,
also taking into account the fact that its expression in
human muscles appears to be significantly lower in com-
parison to murine muscles.
Plasma membrane-associated sialidase NEU3
NEU3, originally described as plasma membrane ganglio-
side sialidase [118-121], is a peripheral or extrinsic
membrane-associated enzyme that has the ability to work
on gangliosides that are located on the same membrane
(cis-activity) or on the membrane of adjacent cells (trans-
activity) [122,123], thus playing a central role in cell-cell
interactions. As a result of NEU3 activity, the cell content
of gangliosides decreases, leading to (i) a modification of
the negative charge on glycocalix, (ii) a modulation of the
cell content of bioactive lipids such as GM3, lactosyl-
ceramide, glucosyl-ceramide and ceramide [10,34,35,124],
(iii) a variation of the chemico/physical properties of lipid
rafts whose clustering represents a pivotal step for mem-
brane fusion during myogenesis [125] and (iv) a modula-
tion of the activity of many canonical and non-canonicalreceptors, such as IR [126], epidermal growth factor re-
ceptor (EGFR) [127] and integrin β4 [128]. Regarding the
latter point, NEU3 has been proposed as a cancer mar-
ker, because its up-regulation was found to promote the
suppression of cell apoptosis in human tumors by a
mechanism dependent on the depletion of gangliosides
and subsequent over-activation of mitogenic receptors
[127-130]. At the plasma membrane, NEU3 specifically
localizes in lipid rafts and caveolae [131,132], microdo-
mains specialized in the recruitment of molecules required
for insulin signaling [133]. Two distinct works have indeed
shown that NEU3 configures as an important regulator of
this signaling along the skeletal muscle/liver axis. In par-
ticular, in skeletal muscle, NEU3 behaves as a negative
regulator of glucose uptake, as in response to insulin the
enzyme was activated by tyrosine phosphorylation and as-
sociation with the growth factor receptor-bound protein 2
(GRB2), leading to accumulation of GM1 and GM2 gang-
liosides which, in turn, reduced the IR phosphorylation
[126]. Accordingly, increasing both NEU3 expression or
GM1 and GM2 levels in the plasma membrane of L6 myo-
cytes and 3T3-L1 adipocytes inhibited IR phosphorylation
[126]. Notably, mice over-expressing the human NEU3 en-
zyme developed a diabetic phenotype associated with
hyperinsulinemia, islets hyperplasia and increased beta-cell
mass [126]. Unlike what was observed in skeletal muscle,
liver NEU3 over-expression positively improved insulin
sensitivity and glucose tolerance in C57BL/6 and insulin-
resistant KKAy mice by increased deposition of glycogen
and triglycerides [134], suggesting that the effects of NEU3
on insulin responsiveness may differ between skeletal
muscle and liver depending on the tissue-specific pattern
of gangliosides.
Over the past years NEU3 has been characterized for its
ability to enhance the activity of EGFR in two distinct
ways, such as direct protein binding [127,130] or depletion
of ganglioside GM3 [135,136]. In fact, NEU3 was found to
promote myogenic differentiation of C2C12 myoblasts by
specifically decreasing the amount of GM3, thereby allow-
ing cell proliferation via EGFR signaling and protection
from apoptotic stimuli [137]. In agreement with this evi-
dence, NEU3 silencing led to an increased threshold of
GM3 levels that caused EGFR inhibition, compromising
the differentiation of C2C12 cells [137]. On the other
hand, another recent study from the same group showed
that NEU3 over-expression in C2C12 myoblasts resulted
in a significant reduction of GM3 that initially slowed the
differentiation by increasing cell proliferation, but then
promoted the formation of hypertrophic myotubes [138].
This particular behavior could be explained by considering
that the greater number of proliferating myoblasts derived
from the enhanced EGFR signaling may be subsequently
engaged in neoformed myotubes, which then display an
increased number of myonuclei. In the same study [138],
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nic acid, a linear α-(2→8)-linked polymer of sialic acid mir-
roring the negative antennas of NCAM, a molecule whose
proper desialylation is crucial for myoblast fusion [88].
Based on these assumptions, it is intriguing to speculate
that the hypertrophic behavior of NEU3-overexpressing
myotubes could be related to the ability of NEU3 to desialy-
late specific surface molecules, such as NCAM.
Overall, NEU3 plays an important role in the control
of insulin responsiveness, in addition to actively partici-
pating in the process of myogenesis by modulation of
gangliosides and, presumably, other surface sialylated
molecules involved in cell-cell recognition and fusion.
Conclusions
Skeletal muscles are supplied from the fusion of multiple
cell elements during embryonic development [139,140].
During the entire lifespan, their size mass is characterized
by continuous remodelling as a result of physical exercise,
chronic illnesses such as HIV, sepsis, diabetes and cancer
cachexia, neuromuscular disorders or aging (sarcopenia)
[141-143]. Sialidases have long been recognized as cata-
bolic enzymes that, working within different subcellular
compartments, can ensure the proper turn-over of glyco-
conjugates by catalyzing the removal of sialic acids resi-
dues. Nevertheless, a growing body of recent literature
indicates that sialidases can specifically influence a num-
ber of different signaling pathways by modifying the cell
content of gangliosides and sialylated receptorial and non-
receptorial proteins. In skeletal muscle what we know is
that the orchestrated expression of the lysosomal NEU1,
cytosolic NEU2 and plasma-membrane NEU3 sialidases
contributes to myoblast proliferation and differentiation,
control of insulin responsiveness and regulation of tissue
architecture by the correct assembly and deposition of
ECM surrounding the myofibers, as schematically illu-
strated in Figure 1. However, there are many things we do
not know about sialidases in various physiological and
pathological conditions of skeletal muscle, and hope-
fully, cell and animal engineering tactics coupled with
proteomics techniques will produce a more complete
characterization of their substrates in order to fully under-
stand their role.
In conclusion, we are confident that a more detailed
understanding of the role of sialidases in skeletal muscle
physiopathology may significantly contribute to open new
exciting frontiers of basic and therapeutic exploration.
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